Диссертация (1174213), страница 41
Текст из файла (страница 41)
– Р. 182-5. doi:10.1161/CIRCOUTCOMES.115.002366.131. Barnett AS. Treatment of Atrial Fibrillation and Concordance Withthe American Heart Association/American College of Cardiology/Heart RhythmSociety Guidelines /Barnett AS, Kim S, Fonarow GC, Thomas LE, ReiffelJA, Allen LA, Freeman JV, Naccarelli G, Mahaffey KW, Go AS, Kowey PR,Ansell JE, Gersh BJ, Hylek EM, Peterson ED, Piccini JP// Circulation: Arrhythmiaand Electrophysiology. – 2017. - №10.
– Р.e005051.132. Başaran Ö. ReAl-life Multicenter Survey Evaluating Strokeprevention strategies in non-valvular atrial fibrillation (RAMSES study) /BaşaranÖ, Beton O, Doğan V, Tekinalp M, Aykan AÇ, Kalaycıoğlu E, Bolat İ, Taşar O,Şafak Ö, Kalçık M, Yaman M, Altun İ, Soylu MÖ, Kırma C, Biteker M; andCollaborators // Anatol J Cardiol. – 2016. - №16(10). - Р.734-741.133. Beyer-Westendorf J.
Effectiveness and safety of dabigatran therapy indaily-care patients with atrial fibrillation. Results from the Dresden NOACRegistry/Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F,Kohler C et al. // Thromb Haemost. – 2015. - №113. – Р.1247–57.134. Beyer-Westendorf J. Drug persistence with rivaroxaban therapy inatrial fibrillation patients-results from the Dresden non-interventional oralanticoagulation registry /Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V,Schreier T, Gobelt M et al. // Europace. – 2015.
- №17. – Р. 530–8.135. Bonde AN. Net clinical benefit of antithrombotic therapy in patientswith atrial fibrillation and chronic kidney disease: a nationwide observationalcohort study /Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, HommelK, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB // J Am Coll Cardiol. –2014. - №64. – Р.2471–2482.248136. Boriani G.
'Real-world' management and outcomes of patients withparoxysmal vs. non-paroxysmal atrial fibrillation in Europe: theEURObservational Research Programme-Atrial Fibrillation (EORP-AF) GeneralPilot Registry /Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI,Rasmussen LH, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GY //Europace. – 2016. - №18(5). – Р.648-57. doi: 10.1093/europace/euv390.137. Bossard M. Determinants of Left Atrial Volume in Patients withAtrial Fibrillation /Bossard M, Kreuzmann R, Hochgruber T, Krisai P,Zimmermann AJ, Aeschbacher S, Pumpol K, Kessel-Schaefer A, Stephan FP,Handschin N, Sticherling C, Osswald S, Kaufmann BA, Paré G, Kühne M, ConenD // PLoS One.
– 2016. - №4. – Р.11(10):e0164145.138. Bress AP. Generalizability of results from the Systolic Blood PressureIntervention Trial (SPRINT) to the US adult population /Bress AP, Tanner RM,Hess R et al. // J. Am. Coll. Cardiol. - 2016. - № 67 (5). – Р.463-72. doi:10.1016/j. jacc.2015.10.037.139. Broderick J.
Guidelines for the management of spontaneousintracerebral hemorrhage in adults: 2007 update: a guideline from the AmericanHeart Association/American Stroke Association Stroke Council, High BloodPressure Research Council, and the Quality of Care and Outcomes in ResearchInterdisciplinary Working group /Broderick J, Connolly S, Feldmann E, Hanley D,Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, ZuccarelloM // Stroke. – 2007. - №38.
- Р.2001–2002140. Camm AJ. Evolving antithrombotic treatment patterns for patientswith newly diagnosed atrial fibrillation /Camm AJ, Accetta G, Ambrosio G, AtarD, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S,Kayani G, Koretsune Y, MantovaniLG, Misselwitz F, Oh S, Turpie AG, VerheugtFW, Kakkar AK; GARFIELD-AF Investigators// Heart.
– 2017. - № 103(4). –Р.307-314.141. Camm AJ. Real-life observations of clinical outcomes with rhythmand rate-control therapies for atrial fibrillation RECORDAF (Registry on CardiacRhythm Disorders Assessing the Control of Atrial Fibrillation) /CammAJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY, MeriouaI, Pedrazzini L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub W // JAm Coll Cardiol. – 2011. -№ 58(5).
– Р.493-501. doi: 10.1016/j.jacc.2011.03.034.142. Carcel C. Degree and Timing of Intensive Blood Pressure Loweringon Hematoma Growth in Intracerebral Hemorrhage: Intensive Blood PressureReduction in Acute Cerebral Hemorrhage Trial-2 Results /Carcel C, Wang X, SatoS, Stapf C, Sandset EC, Delcourt C, Arima H, Robinson T, Lavados P, ChalmersJ, Anderson CS; INTERACT2 Investigators // Stroke. – 2016. - №47(6). – Р.16511653.143. Caro JJ.
Stepped care for hypertension: are the assumption valid?/Caro JJ // J Hypertens. – 1997. - № 15 (Suppl. 7). – Р. 35–9.249144. Castillo J. Blood pressure decrease during the acute phase of ischemicstroke is associated with brain injury and poor stroke outcome /Castillo J, Leira R,Garcia MM et al. // Stroke.
- 2004. - №35. - Р. 520-527145. Chaikriangkrai K. Prevalence and Implications of Subclinical CoronaryArtery Disease in Patients With Atrial Fibrillation /Chaikriangkrai K,Valderrabano M, Bala SK, Alchalabi S, Graviss EA, Nabi F, Mahmarian J, ChangSM // Am J Cardiol. - 2015. - №116(8).
– Р.1219-23. doi:10.1016/j.amjcard.2015.07.041.146. Chan KE. Dabigatran and rivaroxaban use in atrial fibrillation patientson hemodialysis /Chan KE, Edelman ER,Wenger JB, Thadhani RI, Maddux FW//Circulation. – 2015. - №131. – Р.972–979.147. Chao TF. Should atrial fibrillation patients with 1 additional risk factorof the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? /ChaoTF, Liu CJ, Wang KL et al.// J Am Coll Cardiol. - 2015. - V. 65. - P.635–642.148. Chen YL. Mortality prediction using CHADS2/CHA2DS2VASc/R2CHADS2 scores in systolic heart failure patients with or without atrialfibrillation /Chen YL, Cheng CL, Huang JL, Yang NI, Chang HC, Chang KC,Sung SH, Shyu KG, Wang CC, Yin WH, Lin JL, Chen SM; TSOC-HFrEFRegistry investigators and committee //Medicine (Baltimore). – 2017.
-96(43). e8338. doi: 10.1097/MD.0000000000008338.149. Chobanian AV. Seventh report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High Blood Pressure/Chobanian AV, Bakris GL, Black HR et al. // Hypertension. – 2003. - №42. – Р.1206–1252.150. Chronic kidney disease in adults: assessment and management / NICEClinical guideline, 2014. nice.org.uk/guidance/cg182151.
Connolly SJ. Apixaban in patients with atrial fibrillation /Connolly SJ,Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A,Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, JanskyP, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, KimJH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’DonnellM, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering CommitteeInvestigators // N Engl J Med. – 2011.
- №364. – Р.806–817.152. Connolly SJ. Dabigatran versus warfarin in patients with atrialfibrillation /Connolly SJ, Ezekowitz MD, Yusuf S, et al. // N Engl J Med. – 2009. №361. – Р.1139–1151.153. Connolly SJ. Clopidogrel plus aspirin versus oral anticoagulation foratrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan forprevention of Vascular Events (ACTIVE W): a randomised controlled trial/Connolly SJ, Pogue J, Hart R, et al. // Lancet.
– 2006. – 367. – Р.1903–1912.154. Cooper LA. A randomized trial to improve patient-centered care andhypertension control in underserved primary care patients /Cooper LA, Roter DL,Carson KA et al. //J Gen Intern Med. – 2011. - № 26 (11). –Р.1297–1304.250155. Cowan C. The use of anticoagulants in the management of atrialfibrillation among general practices in England /Cowan C, Healicon R,Robson I,Long WR, Barrett J, Fay M, Tyndall K, Gale CP //Heart. – 2013. - №99(16). –Р.1166–1172.156. Cullen MW. Risks and benefits of anticoagulation in atrialfibrillation: insights from the Outcomes Registry for Better Informed Treatment ofAtrial Fibrillation (ORBIT-AF) registry /Cullen MW, Kim S, Piccini JP Sr, AnsellJE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L,Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ; ORBIT-AF Investigators //Circ Cardiovasc Qual Outcomes.
– 2013. - №6(4). – Р. 461-469. doi:10.1161/CIRCOUTCOMES.113.000127.157. Cuspidi C. To better know hypertension: educational meetings forhypertensive patients /Cuspidi C, Lonati L, Sampieri L et al.// Blood Pressure. –2000. - №9. – Р.255–259.158. Cuspidi C. Improvement of patients' knowledge by a singleeducational meeting on hypertension /Cuspidi C, Sampieri L, Macca G et al. // JHum Hypertens.
– 2001. - №15 (1). – Р.57–61.159. Cutler TW. A retrospective descriptive analysis of patient adherence todabigatran at a large academic medical center /Cutler TW, Chuang A, Huynh TD,Witt RG, Branch J, Pon T et al. // J Manag Care Spec Pharm. – 2014. - № 20. –Р.1028–1034.160. Dahal K. Stroke, Major Bleeding, and Mortality Outcomes inWarfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A MetaAnalysis of Observational Studies /Dahal K, Kunwar S, Rijal J, Schulman P, LeeJ//Chest. – 2016. - №149(4).
– Р.951-959. doi: 10.1378/chest.15-1719.161. Deguchi I. Clinical outcomes of persistent and paroxysmal atrialfibrillation in patients with stroke /Deguchi I, Fukuoka T, Hayashi T, MaruyamaH, Sehara Y, Kato Y, Horiuchi Y, Nagamine Y, Sano H, Tanahashi N // J StrokeCerebrovascDis.–2014.№23(10).–Р.2840-2844.doi:10.1016/j.jstrokecerebrovasdis.2014.07.010.162. Deguchi I. Japan Standard Stroke Registry Study Group. Features ofcardioembolic stroke with persistent and paroxysmal atrial fibrillation - a studywith the Japan Stroke Registry /Deguchi I, Hayashi T, Fukuoka T, Kobayashi S,Tanahashi N // Eur J Neurol.
– 2015. - №22. – Р.1215–1219. doi:10.1111/ene.12728.163. Del-Carpio Munoz F. Meta-Analysis of Renal Function on the Safetyand Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation /Del-CarpioMunoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ, PackerDL, Noseworthy PA //Am J Cardiol. – 2016. - №117. – Р.69–75.164. Desteghe L. The Health Buddies App as a Novel Tool to ImproveAdherence and Knowledge in Atrial Fibrillation Patients: A Pilot Study /DestegheL, Kluts K, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, Dendale P,Heidbuchel H // JMIR Mhealth Uhealth.
– 2017. - №5(7). – Р.e98. doi:10.2196/mhealth.7420.251165. Disertori M. Thromboembolic event rate in paroxysmal and persistentatrial fibrillation: data from the GISSI-AF trial /Disertori M, Franzosi MG, BarleraS, Cosmi F, Quintarelli S, Favero C, et al; GISSI-AF Investigators //BMCCardiovasc Disord. – 2013. - №13.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
